

Clinical Trial Protocol

Iranian Registry of Clinical Trials

08 Jun 2026

Evaluation of the effect of three compounds (nystatin, aluminum ammonia, and diphenhydramine), mouthwash, chamomile, and mucosamine spray in the treatment of chemotherapy-induced oral mucositis in malignancy in children with leukemia

Protocol summary

Study aim

Evaluation of the effect of three-component mouthwash (nystatin, aluminum ammonia and diphenhydramine), chamomile and mucosamine spray in the treatment of chemotherapy-induced oral mucositis in pediatric malignancy

Design

This study is a double blind clinical trial (statistical specialist and data collector blinding) parallel to phase 3. Two-sided blind and randomized into three groups. The Rand function in Excel software will be used for randomization.

Settings and conduct

Pediatric Blood and Oncology Department of Amirkabir Hospital, Arak. Three groups of routine treatment (A), chamomile mouthwash (B) and mucosamine (C), Group A: Routine treatment Group B routine treatment + chamomile Group C: Routine treatment + mucosamine

Participants/Inclusion and exclusion criteria

Inclusion criteria: Full consciousness, Hospitalized in the oncology ward of Arak Children's Hospital, Similar treatment protocol, Minimum age 2 years and maximum 16 years, Having oral mucosa (minimum score 1), No history of, chamomile mouthwash and mucosamine spray No entry conditions : Dissatisfaction with research, continuous use of painkillers and drugs, gum disease

Intervention groups

The three-combination mouthwash is intended as a routine treatment for such children who roll in the morning for 1 minute to 14 days (in all three groups). • In the chamomile group, use chamomile mouthwash for a week, after brushing. Dilute 15 drops of the solution in 10 cc of water, rinse for one minute and do not eat for an hour (B). In the mucosamine group, in addition to prescribing a three-component mouthwash, mucosamine is sprayed 3 times a day on the entire mucous

membrane of the patient's mouth. (Receive daily spray until the 14th day). (Group C) All participants in all three groups receive routine intervention.

Main outcome variables

Severity of oral mucositis

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20210228050519N1**

Registration date: **2021-12-27, 1400/10/06**

Registration timing: **registered_while_recruiting**

Last update: **2021-12-27, 1400/10/06**

Update count: **0**

Registration date

2021-12-27, 1400/10/06

Registrant information

Name

Khalil Namazi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 86 3417 3505

Email address

namazikhalil44@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-12-21, 1400/09/30

Expected recruitment end date

2022-12-21, 1401/09/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of the effect of three compounds (nystatin, aluminum ammonia, and diphenhydramine), mouthwash, chamomile, and mucosamine spray in the treatment of chemotherapy-induced oral mucositis in malignancy in children with leukemia

Public title

The effect of three-component mouthwash (nystatin, aluminum MGS and diphenhydramine), chamomile and mucosamine spray in the treatment of oral mucositis caused by chemotherapy

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Full consciousness Hospitalized in the oncology ward of Arak Children's Hospital No gum disease Lack of continuous use of painkillers and drugs Similar treatment protocol Minimum age 2 years and maximum 16 years Having oral mucosa (minimum score 1) No history of chamomile mouthwash and mucosamine spray

Exclusion criteria:

Improvement of oral mucosa before randomization

Age

From **2 years** old to **16 years** old

Gender

Both

Phase

3

Groups that have been masked

- Outcome assessor
- Data analyser

Sample size

Target sample size: **90**

Randomization (investigator's opinion)

Randomized

Randomization description

All children are admitted to the study according to the inclusion criteria and sampling is done in an accessible and easy way. In this study, randomized block method will be used to randomize the three groups of routine treatment (group A), chamomile mouthwash treatment (group B) and mucosamine spray treatment (group C). Children will be divided into three equal groups (A / B / C) using random allocation. In order to perform random allocation, the randomized blocking method with 6 blocks such as AABCC, ABBACC, BBAACC, AACBB, BBCCAA, ACBCAB, etc. will be used, which will have numbers from 1 onwards. Then, by randomly selecting numbers from 1 to n, random sequences of three types of drugs will be identified for the studied samples.

Blinding (investigator's opinion)

Double blinded

Blinding description

In this study, the statistical expert and the evaluator of the outcome are not aware of the type of drug used, so the study is double-blind.

Placebo

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Arak University of Medical Sciences

Street address

Payambar aazam (SAW) University Complex, Basij SQ, Sardasht region

City

Arak

Province

Markazi

Postal code

6941-7-38481

Approval date

2021-10-17, 1400/07/25

Ethics committee reference number

IR.ARAKMU.REC.1400.184

Health conditions studied**1****Description of health condition studied**

Severity of oral mucositis

ICD-10 code

K12.3

ICD-10 code description

موکوزیت دهانی

Primary outcomes**1****Description**

Severity of oral mucositis

Timepoint

On the first day (before the intervention), the seventh day and the fourteenth day

Method of measurement

Mucosal severity instrument with a scoring range of 0 to 4

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: Before starting chemotherapy, all subjects will be taught the correct way to observe oral hygiene, including brushing and flossing. All participants received a three-combination mouthwash (nystatin, aluminum ammojas, and diphenhydramine) as a routine treatment for such children who rolled for 1 minute once a day in the morning (receiving daily mouthwash until the 14th day). After mouthwash, patients do not consume food or fluids for up to 1 hour (group A).

Category

Treatment - Drugs

2

Description

Intervention group: • In the chamomile group, use chamomile mouthwash available in pharmacies for a week, three times a day (morning, noon, night) after brushing. Dilute 15 drops of the solution in 10 cc of water and gargle for one minute and do not eat for an hour after that, and the previous standard treatment of the treating physician will continue except for the use of topical mouthwash (group B). (Receive daily mouthwash until the 14th day).

Category

Treatment - Drugs

3

Description

In the mucosamine group (water, sodium, glanzine, propylene glycol, lysine, leucine and proline) in addition to the three-combination mouthwash, mucosamine is sprayed 3 times a day on the entire mucous membrane of the patient's mouth (group C) (spray received) Daily until the 14th day). No drug interactions have been reported for this drug

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Amirkabir Hospital, Arak

Full name of responsible person

Khalil Namazi

Street address

Central Province of Arak, Shahid Shiroodi St. Railway, Amirkabir Hospital

City

arak

Province

Markazi

Postal code

38196 91187

Phone

+98 86 3313 5075

Email

namazikhalil44@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Alireza Kamali

Street address

Deputy of research and technology, Payambar aazam (SAW) University Complex, Basij SQ, Sardasht region

City

Arak

Province

Markazi

Postal code

3848176941

Phone

+98 86 3417 3645

Email

nnamazikhalil44@gmail.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Arak University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Khalil Namazi

Position

Student

Latest degree

Medical doctor

Other areas of specialty/work

Pediatrics

Street address

Payambar aazam (SAW) University Complex Basij
Square of the University Complex

City

Arak

Province

Markazi

Postal code

3819693345

Phone

+98 914 451 3811

Email

namazikhalil44@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

khalil namazi

Position

student

Latest degree

Medical doctor

Other areas of specialty/work

Pediatrics

Street address

Payambar aazam (SAW) University Complex Basij
Square of the University Complex

City

arak

Province

Markazi

Postal code

3819693345

Phone

+98 914 451 3811

Email

namazikhalil44@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Khalil namazi

Position

Student

Latest degree

Medical doctor

Other areas of specialty/work

Pediatrics

Street address

Payambar aazam, University Complex Basij Square of
the University Complex

City

Arak

Province

Markazi

Postal code

3819693345

Phone

+98 914 451 3811

Email

namazikhalil44@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to
make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to
make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to
make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to
make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to
make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to
make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to
make this available